|
MechanismSARS-CoV-2 antigen inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date14 May 2021 |
|
MechanismBacterial DNA gyrase inhibitors [+2] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Yong Yu (China) Pharmaceutical Enterprise Management Co. Ltd.
0 Patents (Medical) associated with Yong Yu (China) Pharmaceutical Enterprise Management Co. Ltd.
100 Deals associated with Yong Yu (China) Pharmaceutical Enterprise Management Co. Ltd.
100 Translational Medicine associated with Yong Yu (China) Pharmaceutical Enterprise Management Co. Ltd.